^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    T3011

    i
    Associations
    News

    Trials

    Company:
    ImmVira Pharma, Shanghai Pharma
    Drug class:
    PD1 inhibitor, IL-12 stimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma (NCT05756556)
    Phase 2
    ImmVira Pharma Co. Ltd
    Suspended
    Last update posted :
    02/01/2024
    Initiation :
    06/30/2024
    Primary completion :
    12/31/2026
    Completion :
    01/01/2027
    BRAF
    |
    BRAF V600E • BRAF V600 • BRAF V600K • RAS mutation • BRAF V600E + BRAF V600K
    |
    Cotellic (cobimetinib) • T3011
    A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (NCT04370587)
    Phase 1/2
    ImmVira Pharma Co. Ltd
    Recruiting
    Last update posted :
    08/29/2023
    Initiation :
    09/17/2020
    Primary completion :
    10/31/2023
    Completion :
    10/31/2025
    EGFR • ALK
    |
    ALK rearrangement
    |
    Keytruda (pembrolizumab) • T3011